Shiao-Wen David Hsu, MD

Assistant Professor of Medicine
William Dalton Family Assistant Professor of Medical Oncology, in the School of Medicine
Member of the Duke Cancer Institute
Campus mail Dept Of Medicine, Box 3233, Durham, NC 27710
Phone (919) 681-3480
Email address shiaowen.hsu@duke.edu

Education and Training

  • Fellow in Hematology-Oncology, Medicine, Duke University, 2004 - 2007
  • Medical Resident, Medicine, University of Texas at Dallas, 2001 - 2004
  • M.D., University of North Carolina at Chapel Hill, 2001

Publications

Mettu, NB, Hurwitz, H, and Hsu, DS. "Use of molecular biomarkers to inform adjuvant therapy for colon cancer." ONCOLOGY (United States) 27, no. 8 (August 14, 2013). (Review)

Scholars@Duke

Morse, MA, Chaudhry, A, Gabitzsch, ES, Hobeika, AC, Osada, T, Clay, TM, Amalfitano, A, Burnett, BK, Devi, GR, Hsu, DS, Xu, Y, Balcaitis, S, Dua, R, Nguyen, S, Balint, JP, Jones, FR, and Lyerly, HK. "Novel adenoviral vector induces T-cell responses despite anti-adenoviral neutralizing antibodies in colorectal cancer patients." Cancer Immunol Immunother 62, no. 8 (August 2013): 1293-1301.

PMID
23624851
Full Text

Zani, S, Papalezova, K, Stinnett, S, Tyler, D, Hsu, D, and Blazer, DG. "Modest advances in survival for patients with colorectal-associated peritoneal carcinomatosis in the era of modern chemotherapy." J Surg Oncol 107, no. 4 (March 2013): 307-311.

PMID
22811275
Full Text

Uronis, HE, Bendell, JC, Altomare, I, Blobe, GC, Hsu, SD, Morse, MA, Pang, H, Zafar, SY, Conkling, P, Favaro, J, Arrowood, CC, Cushman, SM, Meadows, KL, Brady, JC, Nixon, AB, and Hurwitz, HI. "A phase II study of capecitabine, oxaliplatin, and bevacizumab in the treatment of metastatic esophagogastric adenocarcinomas." Oncologist 18, no. 3 (2013): 271-272.

PMID
23485624
Full Text

Zani, S, Papalezova, K, Stinnett, S, Tyler, D, Hsu, D, and III, DGB. "Modest advances in survival for patients with colorectal-associated peritoneal carcinomatosis in the era of modern chemotherapy." Journal of Surgical Oncology 107, no. 4 (2013): 307-311.

Full Text

Morse, MA, Chaudhry, A, Gabitzsch, ES, Hobeika, AC, Osada, T, Clay, TM, Amalfitano, A, Burnett, BK, Devi, GR, Hsu, DS, Xu, Y, Balcaitis, S, Dua, R, Nguyen, S, Jr, JPB, Jones, FR, and Lyerly, HK. "Novel adenoviral vector induces T-cell responses despite anti-adenoviral neutralizing antibodies in colorectal cancer patients." Cancer Immunology, Immunotherapy 62, no. 8 (2013): 1293-1301.

Full Text

Kim, MK, Osada, T, Barry, WT, Yang, XY, Freedman, JA, Tsamis, KA, Datto, M, Clary, BM, Clay, T, Morse, MA, Febbo, PG, Lyerly, HK, and Hsu, DS. "Characterization of an oxaliplatin sensitivity predictor in a preclinical murine model of colorectal cancer." Mol Cancer Ther 11, no. 7 (July 2012): 1500-1509.

PMID
22351745
Full Text

Riedel, RF, Porrello, A, Pontzer, E, Chenette, EJ, Hsu, DS, Balakumaran, B, Potti, A, Nevins, J, and Febbo, PC. "Retraction in part: A genomic approach to identify molecular pathways associated with chemotherapy resistance." Mol Cancer Ther 11, no. 5 (May 2012): 1214-1215.

PMID
22461660
Full Text

Acharya, CR, Hsu, DS, Anders, CK, Anguiano, A, Salter, KH, Walters, KS, Redman, RC, Tuchman, SA, Moylan, CA, Mukherjee, S, Barry, WT, Dressman, HK, Ginsburg, GS, Marcom, KP, Garman, KS, Lyman, GH, Nevins, JR, and Potti, A. "Retraction: Acharya CR, et al. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer. JAMA. 2008;299(13):1574-1587." JAMA 307, no. 5 (February 1, 2012): 453-.

PMID
22228686
Full Text

Uronis, JM, Osada, T, McCall, S, Yang, XY, Mantyh, C, Morse, MA, Lyerly, HK, Clary, BM, and Hsu, DS. "Histological and molecular evaluation of patient-derived colorectal cancer explants." PLoS One 7, no. 6 (2012): e38422-.

PMID
22675560
Full Text

Pages